Neisseria meningitidis - Revision history

Danbot: Fix typo: Meningcococcal → Meningococcal

2026-03-20T11:32:33Z

Fix typo: Meningcococcal → Meningococcal

← Older revision		Revision as of 11:32, 20 March 2026
Line 172:		Line 172:
	*{{AntibioticDose\|drug=Rifampin\|dose=600 mg PO BID for two days\|context=Neisseria meningitidis\|disease=Neisseria meningitidis\|population=Adult}}		*{{AntibioticDose\|drug=Rifampin\|dose=600 mg PO BID for two days\|context=Neisseria meningitidis\|disease=Neisseria meningitidis\|population=Adult}}
	====Pediatric====		====Pediatric====
	*{{AntibioticDose\|drug=Rifampin\|dose=<1 mo; 5mg/kg PO/IV q24h x4 days; Max: 600 mg/day; 1+ mo; 10 mg/kg PO/IV q24h x4 days; Max: 600 mg/day\|context=~~Meningcococcal~~ prophylaxis\|disease=Neisseria meningitidis\|population=Pediatric}}		*{{AntibioticDose\|drug=Rifampin\|dose=<1 mo; 5mg/kg PO/IV q24h x4 days; Max: 600 mg/day; 1+ mo; 10 mg/kg PO/IV q24h x4 days; Max: 600 mg/day\|context=Meningococcal prophylaxis\|disease=Neisseria meningitidis\|population=Pediatric}}

	==See Also==		==See Also==

2026-03-20T10:59:24Z

Add Rifampin AntibioticDose entries

← Older revision		Revision as of 10:59, 20 March 2026
Line 164:		Line 164:
	==Table Overview==		==Table Overview==
	{{Clinically Relevant Bacteria}}		{{Clinically Relevant Bacteria}}


			==Management==

			===Antibiotic Dosing===
			====Adult====
			*{{AntibioticDose\|drug=Rifampin\|dose=600 mg PO BID for two days\|context=Neisseria meningitidis\|disease=Neisseria meningitidis\|population=Adult}}
			====Pediatric====
			*{{AntibioticDose\|drug=Rifampin\|dose=<1 mo; 5mg/kg PO/IV q24h x4 days; Max: 600 mg/day; 1+ mo; 10 mg/kg PO/IV q24h x4 days; Max: 600 mg/day\|context=Meningcococcal prophylaxis\|disease=Neisseria meningitidis\|population=Pediatric}}

	==See Also==		==See Also==

2022-11-02T20:38:32Z

Clinical Features

← Older revision		Revision as of 20:38, 2 November 2022
Line 5:		Line 5:

	==Clinical Features==		==Clinical Features==
			[[File:Meningitis-Epidemics-World-Map.png\|thumb\|Epidemic meningitis geographic distribution showing "meningitis belt."]]
			[[File:Charlotte Cleverley-Bisman Meningicoccal Disease.jpg\|thumb\|Severe [[meningococcal]] meningitis with classic petechial rash progressing to gangrene.]]
	*A cause of [[meningitis]]		*A cause of [[meningitis]]
	*Rash		*Rash

2022-11-02T20:32:59Z

Clinical Features

← Older revision		Revision as of 20:32, 2 November 2022
Line 5:		Line 5:

	==Clinical Features==		==Clinical Features==
	*A cause [[meningitis]]		*A cause of [[meningitis]]
	*Rash		*Rash
	**Approximately 2/3 of patients with [[meningococcemia]] develop rash.<ref>Sara Bode; Contagious Exanthematous Diseases. ''Quick References 2022''; 10.1542/aap.ppcqr.396150</ref>		**Approximately 2/3 of patients with [[meningococcemia]] develop rash.<ref>Sara Bode; Contagious Exanthematous Diseases. ''Quick References 2022''; 10.1542/aap.ppcqr.396150</ref>

2022-11-02T20:32:48Z

← Older revision		Revision as of 20:32, 2 November 2022
Line 3:		Line 3:
	==Background==		==Background==
	*[[Gram negative bacteria\|Gram negative]] diplococci that causes [[bacterial meningitis]]		*[[Gram negative bacteria\|Gram negative]] diplococci that causes [[bacterial meningitis]]

			==Clinical Features==
			*A cause [[meningitis]]
			*Rash
			**Approximately 2/3 of patients with [[meningococcemia]] develop rash.<ref>Sara Bode; Contagious Exanthematous Diseases. ''Quick References 2022''; 10.1542/aap.ppcqr.396150</ref>
			**Can include erythematous, morbilliform, or urticarial macules and papules<ref>Sara Bode; Contagious Exanthematous Diseases. ''Quick References 2022''; 10.1542/aap.ppcqr.396150</ref>
			**Most common hallmark is purpuric lesions with jagged edges. <ref>Sara Bode; Contagious Exanthematous Diseases. ''Quick References 2022''; 10.1542/aap.ppcqr.396150</ref>

	==Post exposure prophylaxis==		==Post exposure prophylaxis==

2021-01-18T21:37:30Z

Background

← Older revision		Revision as of 21:37, 18 January 2021
Line 2:		Line 2:

	==Background==		==Background==
	*Gram negative diplococci that causes [[bacterial meningitis]]		*[[Gram negative bacteria\|Gram negative]] diplococci that causes [[bacterial meningitis]]

	==Post exposure prophylaxis==		==Post exposure prophylaxis==

2021-01-15T19:56:26Z

Background

← Older revision		Revision as of 19:56, 15 January 2021
Line 2:		Line 2:

	==Background==		==Background==
			*Gram negative diplococci that causes [[bacterial meningitis]]

	==Post exposure prophylaxis==		==Post exposure prophylaxis==
	{{Neisseria meningitis prophylaxis}}		{{Neisseria meningitis prophylaxis}}

2016-09-04T14:02:40Z

Background

← Older revision		Revision as of 14:02, 4 September 2016
Line 2:		Line 2:

	==Background==		==Background==
			==Post exposure prophylaxis==
			{{Neisseria meningitis prophylaxis}}

	==[[Antibiotic Sensitivities]]<ref>Sanford Guide to Antimicrobial Therapy 2014</ref>==		==[[Antibiotic Sensitivities]]<ref>Sanford Guide to Antimicrobial Therapy 2014</ref>==

2014-11-03T18:34:36Z

← Older revision		Revision as of 18:34, 3 November 2014
Line 1:		Line 1:
			''See [[meningitis]] for a general approach to the disease entity''

	==Background==		==Background==

2014-07-23T19:20:18Z

← Older revision	Revision as of 19:20, 23 July 2014
(No difference)